We actively communicate on our business, services and technical capabilities. Use the resources on this page to browse through recent news, to subscribe to our news services or to meet us at one of our forthcoming events.
PolyPeptide and Numaferm announce partnership to leverage their expertise for the more sustainable production of peptide-based APIs
9 May 2023 - Baar (Switzerland) and Düsseldorf (Germany), 9 May 2023 – PolyPeptide, a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (APIs), and Numaferm, a German […]
Read morePolyPeptide announces results of the annual General Meeting 2023
12 Apr 2023 - Baar, 12 April 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), today announced that […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2023
22 Mar 2023 - Baar, 22 March 2023 – PolyPeptide Group AG (SIX: PPGN), a focused global CDMO for peptide- and oligonucleotide-based active pharmaceutical ingredients (the “Company”), published today the […]
Read moreMonika Casanova joining PolyPeptide as CHRO and member of the PMC
9 May 2022 - With 19 years of HR experience, the native German most recently worked as head of global HR for a building materials company.
Read morePolyPeptide announces results of the annual General Meeting 2022
26 Apr 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide development and manufacturing, today announced that the shareholders approved all proposals put forward by the Board of […]
Read morePolyPeptide publishes invitation to the annual General Meeting 2022
1 Apr 2022 - PolyPeptide Group AG (PolyPeptide), a global leader in peptide custom development and manufacturing, published today the invitation to its first annual General Meeting which will take […]
Read morePolyPeptide customer Cara Therapeutics with FDA approval for novel treatment of moderate-to-severe pruritus in hemodialysis patients
1 Sep 2021 - Long-term collaborative development process for peptide API successfully completed and continued with commercial supply agreement PolyPeptide is pleased to announce that its customer Cara Therapeutics (Nasdaq: […]
Read morePolyPeptide Group appoints Raymond De Vré as new Chief Executive Officer
16 Feb 2021 - PolyPeptide Group, a global leader in peptide manufacturing and development, today announced the appointment of as its new Chief Executive Officer. He will succeed Jane Salik […]
Read morePolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine
4 Jun 2020 - The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax […]
Read more